Is Becton, Dickinson and Company Stock Underperforming the Nasdaq?

Becton, Dickinson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Valued at $55.4 billion by market cap, the company offers solutions that help advance medical research and genomics, enhance the diagnosis of infectious diseases and cancer, improve medication management, and promote infection prevention.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and BDX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical instruments & supplies industry. BDX excels in medical technology, with a strong global brand, an extensive distribution network, and a broad product portfolio. Its commitment to innovation, significant R&D investments, and strategic acquisitions drives growth, while its robust manufacturing and supply chain ensure reliable product delivery, positioning BDX as a leader in the healthcare industry.